Deutsche Bank AG Has $403,000 Holdings in Strongbridge Biopharma (SBBP)

Deutsche Bank AG raised its stake in Strongbridge Biopharma (NASDAQ:SBBP) by 185.0% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 55,711 shares of the biotechnology company’s stock after acquiring an additional 36,160 shares during the quarter. Deutsche Bank AG owned approximately 0.14% of Strongbridge Biopharma worth $403,000 at the end of the most recent reporting period.

A number of other large investors also recently made changes to their positions in the business. Broadfin Capital LLC lifted its holdings in Strongbridge Biopharma by 10.4% in the fourth quarter. Broadfin Capital LLC now owns 3,186,695 shares of the biotechnology company’s stock valued at $23,104,000 after acquiring an additional 299,900 shares during the period. Armistice Capital LLC lifted its holdings in Strongbridge Biopharma by 69.4% in the fourth quarter. Armistice Capital LLC now owns 2,870,000 shares of the biotechnology company’s stock valued at $20,808,000 after acquiring an additional 1,175,400 shares during the period. BlackRock Inc. lifted its holdings in Strongbridge Biopharma by 57.5% in the fourth quarter. BlackRock Inc. now owns 1,432,365 shares of the biotechnology company’s stock valued at $10,385,000 after acquiring an additional 522,875 shares during the period. Opaleye Management Inc. lifted its holdings in Strongbridge Biopharma by 5.9% in the fourth quarter. Opaleye Management Inc. now owns 1,250,000 shares of the biotechnology company’s stock valued at $9,062,000 after acquiring an additional 70,000 shares during the period. Finally, Stonepine Capital Management LLC acquired a new position in Strongbridge Biopharma in the fourth quarter valued at approximately $2,496,000. 58.41% of the stock is owned by institutional investors.

Shares of Strongbridge Biopharma opened at $7.70 on Friday, Marketbeat.com reports. The company has a debt-to-equity ratio of 41.16, a current ratio of 8.90 and a quick ratio of 8.74. The company has a market cap of $352.89 million, a PE ratio of -5.31 and a beta of 1.04. Strongbridge Biopharma has a 1-year low of $7.65 and a 1-year high of $7.80.

Strongbridge Biopharma (NASDAQ:SBBP) last announced its earnings results on Thursday, May 10th. The biotechnology company reported ($0.66) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.41) by ($0.25). The business had revenue of $3.87 million for the quarter, compared to analyst estimates of $3.25 million. Strongbridge Biopharma had a negative return on equity of 1,224.30% and a negative net margin of 1,032.62%. sell-side analysts forecast that Strongbridge Biopharma will post -1.94 earnings per share for the current fiscal year.

SBBP has been the subject of several research analyst reports. Zacks Investment Research raised Strongbridge Biopharma from a “sell” rating to a “hold” rating in a research note on Friday, April 6th. ValuEngine raised Strongbridge Biopharma from a “sell” rating to a “hold” rating in a research note on Wednesday, May 2nd. Cantor Fitzgerald reaffirmed a “buy” rating and set a $14.00 target price on shares of Strongbridge Biopharma in a research note on Monday, March 12th. HC Wainwright reaffirmed a “buy” rating on shares of Strongbridge Biopharma in a research note on Friday, May 11th. Finally, BidaskClub raised Strongbridge Biopharma from a “buy” rating to a “strong-buy” rating in a research note on Thursday, March 22nd. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and three have given a buy rating to the company’s stock. Strongbridge Biopharma currently has an average rating of “Hold” and an average price target of $12.81.

Strongbridge Biopharma Company Profile

Strongbridge Biopharma plc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs. The company's commercial products include Keveyis, an oral carbonic anhydrase inhibitor for treating hyperkalemic, hypokalemic, and related variants of primary periodic paralysis in the United States; and Macrilen, an oral growth hormone secretagogue receptor agonist for use in the diagnosis of patients with adult growth hormone deficiency in the United States and Canada.

Want to see what other hedge funds are holding SBBP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Strongbridge Biopharma (NASDAQ:SBBP).

Institutional Ownership by Quarter for Strongbridge Biopharma (NASDAQ:SBBP)

Receive News & Ratings for Strongbridge Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Strongbridge Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply